MedTrace Logo

AZD9668 Relative Bioavailability

NCT01035411 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-01-29

No results posted yet for this study

Summary

This clinical study will aid future formulation development and optimisation of AZD9668 tablets by evaluating possible effects of minor changes to the formulation and process on the rate and extent of absorption.

Conditions

Interventions

DRUG

AZD9668

2 x 30 mg batch DLE494

DRUG

AZD9668

2 x 30 mg batch DLF497

DRUG

AZD9668

2 x 30 mg tablet variant 1

Sponsors & Collaborators

Principal Investigators

  • Emma Harrop · AstraZeneca R&D

  • Rainard Fuhr · Parexel

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01035411 on ClinicalTrials.gov